ACST Stock – (NASDAQ: ACST) is providing an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of the “at the market” equity of its offering program.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out a “at the market” equity offering system under which Acasti may issue and promote from time to time the common shares of its having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were marketed at prevailing market prices averaging US$1.0747 per share. No securities were sold through the facilities of the TSXV or, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will supply the Company with supplemental flexibility in its ongoing review process to check out as well as evaluate strategic options.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription drugs using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy and safety for lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with serious HTG.
Forward Looking Statements – ACST Stock
Statements in this press release which aren’t statements of historical or current truth constitute “forward looking information” within the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements involve known and unknown risks, uncertainties, and other unknown elements that might result in the particular results of Acasti to be materially different from historical success and from any later outcomes expressed or implied by such forward looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are actually urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this particular press release. Forward-looking assertions in that press release include, but aren’t restricted to, information or statements concerning Acasti’s strategy, succeeding operations and its review of strategic options.
The forward looking assertions contained in this specific press release are expressly qualified in their entirety by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area contained in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor aisle of Acasti’s site at www.acastipharma.com. All forward-looking statements in that press release are produced as of the particular date of this press release.
ACST Stock – Acasti doesn’t undertake to update some such forward-looking statements whether as a direct result of info that is brand new , future events or even otherwise, except as required by law. The forward looking statements contained herein are also subject generally to assumptions and risks as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage